User menu

Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.

Bibliographic reference Osselaer, Jean-Claude ; Doyen, Chantal ; Defoin, Laurence ; Debry, Cecile ; Goffaux, Maité ; et. al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.. In: Transfusion, Vol. 49, no. 7, p. 1412-22 (2009)
Permanent URL http://hdl.handle.net/2078.1/22290
  1. Harris, Blood banking and transfusion medicine, 183 (2007)
  2. Blajchman, Transfus Med Rev, 19, 259 (2005)
  3. Rebulla, N Engl J Med, 337, 1870 (1997)
  4. TRAP Study Group, N Engl J Med, 337, 1861 (1997)
  5. Tinmouth, Transfus Med Rev, 17, 181 (2003)
  6. Slichter, J Clin Apher, 21, 78 (2006)
  7. Slichter, American Society of Hematology education program book, 172 (2007)
  8. Osselaer, Vox Sang, 91, 180 (2006)
  9. 9.  Cazenave JP . Proceedings of a consensus conference: pathogen inactivation-making decisions about new technologies. Clinical experience with pathogen-inactivated platelets. Transfusion Med Reviews 2008;22:1-34.
  10. Klein, Transfusion, 47, 2338 (2007)
  11. van Rhenen, Blood, 101, 2426 (2003)
  12. McCullough, Blood, 104, 1534 (2004)
  13. Janetzko, Transfusion, 45, 1443 (2005)
  14. 14. Belgian Law of 8 December 1992 on privacy protection in relation to the processing of personal data as modified by the law of 11 December 1998 implementing Directive 95/46 EC and the law of 26 February 2003. Belgium: Belgian State Gazette; 2003.
  15. Snyder, Transfusion, 44, 1732 (2004)
  16. Murphy, Transfusion, 46, 24 (2006)
  17. Osselaer, Vox Sang, 94, 315 (2008)
  18. Osselaer, Transfusion, 48, 1061 (2008)